Zacks: Analysts Expect Dextera Surgical Inc. (DXTR) Will Post Quarterly Sales of $620,000.00
Wall Street analysts expect that Dextera Surgical Inc. (NASDAQ:DXTR) will announce $620,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dextera Surgical’s earnings, with the lowest sales estimate coming in at $570,000.00 and the highest estimate coming in at $670,000.00. Dextera Surgical posted sales of $470,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 31.9%. The company is scheduled to report its next quarterly earnings results after the market closes on Thursday, November 9th.
According to Zacks, analysts expect that Dextera Surgical will report full-year sales of $620,000.00 for the current financial year, with estimates ranging from $3.75 million to $3.87 million. For the next year, analysts forecast that the business will report sales of $7.21 million per share. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Dextera Surgical.
Dextera Surgical (NASDAQ:DXTR) last issued its earnings results on Tuesday, August 8th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.29). The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.03 million.
A number of equities analysts have weighed in on DXTR shares. Ladenburg Thalmann Financial Services started coverage on Dextera Surgical in a research note on Wednesday, August 16th. They set a “buy” rating and a $0.80 price objective for the company. Zacks Investment Research lowered Dextera Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Wedbush reduced their price objective on Dextera Surgical from $3.50 to $0.70 and set an “outperform” rating for the company in a research note on Wednesday, July 12th.
TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/zacks-analysts-expect-dextera-surgical-inc-dxtr-will-post-quarterly-sales-of-620000-00/1684012.html.
Shares of Dextera Surgical (NASDAQ DXTR) traded up $0.02 during mid-day trading on Wednesday, reaching $0.21. The company had a trading volume of 4,518,183 shares, compared to its average volume of 7,299,771. The company has a quick ratio of 0.59, a current ratio of 0.71 and a debt-to-equity ratio of -0.41. Dextera Surgical has a one year low of $0.11 and a one year high of $2.33.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Perkins Capital Management Inc. purchased a new position in shares of Dextera Surgical during the 2nd quarter valued at about $100,000. Broadfin Capital LLC raised its stake in shares of Dextera Surgical by 64.7% during the 2nd quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 388,080 shares during the last quarter. Finally, Virtu KCG Holdings LLC raised its stake in shares of Dextera Surgical by 1,380.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 344,933 shares during the last quarter. Institutional investors and hedge funds own 6.18% of the company’s stock.
About Dextera Surgical
Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.